Exploring comorbidities in Colombian psoriasis patients aged 15+: insights from real-world data

Background: Psoriasis is a chronic, immune-mediated inflammatory disorder affecting skin and joints, primarily affecting individuals between 18-39 and 50-69 years, with a prevalence which varies globally, with significant comorbidities impacting quality of life. Psoriasis is now recognized as a systemic inflammatory disease involving both genetic and environmental factors. Comorbidities include cardiovascular disease and metabolic disorders, underlining the need for further research and tailored treatment in Colombia. Methods: This retrospective observational study analyzed data from the Colombian Ministry of Health's SISPRO database, focusing on individuals over 15 years diagnosed with psoriasis between 2018 and 2022. Using ICD-10 codes, psoriasis and its comorbidities—such as cardiovascular, metabolic, and autoimmune conditions—were identified. Descriptive statistics characterized the subjects, and the coexistence of psoriasis with comorbidities was assessed. Results: A total of 115,725 individuals were diagnosed with psoriasis in Colombia between 2018-2022, yielding a prevalence of 2.89 per thousand, with higher rates in older populations. The study examined the comorbidities associated with psoriasis, founding a strong association with atopic dermatitis (PR 6.28), tinea unguium (PR 6.05) and tuberculosis (PR 3.04). Comorbid prevalence rates for conditions like diabetes, hypertension, obesity, and dyslipidemia were notably elevated in psoriasis patients, with increased risks (PR) across multiple conditions. These findings highlight the broad spectrum of comorbidities associated with psoriasis. Conclusions: This study is a crucial first step in understanding the comorbidities associated with psoriasis in Colombia. It underscores the need for further research to better understand the systemic nature of psoriasis and improve patient care and treatment strategies.